HCG

What is HCG?#

HCG is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

Mechanism of Action#

Human chorionic gonadotropin (hCG) is a heterodimeric glycoprotein hormone that binds and activates the luteinizing hormone/chorionic gonadotropin receptor (LHCGR), a class A GPCR expressed in gonadal and reproductive tissues. High-resolution structures show hCG engages the large extracellular domain (ECD) and activates the transmembrane core via a hinge “push–pull” mechanism in which a conserved hinge loop fragment (P10) functions as a tethered agonist, stabilizing an active 7TM conformation that couples to G proteins and β-arrestins (simoniUnknownyearoggettoendocrinereviewsproposal pages 19-20). Ligand-specific contacts at the ECD/hinge and hormone glycosylation underlie biased signaling differences between hCG and LH (casariniUnknownyearadvancearticle pages 17-18).

Canonical Gs–cAMP–PKA signaling and steroidogenesis • LHCGR–Gs activates adenylyl cyclase, elevating cAMP and activating PKA. PKA phosphorylates CREB and promotes transcription of steroidogenic genes, notably STARD1 (StAR) and CYP enzymes including CYP11A1, coordinating cholesterol transfer to mitochondria and conversion to pregnenolone; StAR phosphorylation and expression are integral to the acute steroidogenic response. In human granulosa-lutein cells, hCG is about fivefold more potent than LH for cAMP generation and produces slower, sustained cAMP kinetics; this bias correlates with stronger CRE-driven transcription and sustained steroidogenic drive and progesterone output under equipotent stimulation.

β-arrestin recruitment, receptor trafficking, and endosomal signaling • Agonist-occupied LHCGR is phosphorylated by GRKs, recruits β-arrestins, and internalizes. β-arrestins scaffold MAPK components to generate a delayed ERK1/2 wave and associate with PDEs to modulate cAMP microdomains. Internalized LHCGR can remain signaling-competent in endosomes, forming complexes with G proteins and β-arrestins that sustain cAMP (regulated by APPL1) (simoniUnknownyearoggettoendocrinereviewsproposal pages 20-22). Compared with LH, hCG more effectively promotes β-arrestin-2 recruitment, receptor aggregation/internalization, and sustained cAMP, supporting ligand-biased outcomes (casariniUnknownyearadvancearticle pages 20-21, simoniUnknownyearoggettoendocrinereviewsproposal pages 20-22).

ERK/MAPK and PI3K/AKT pathways • LHCGR activation also engages ERK/MAPK and PI3K/AKT. ERK and AKT contribute to survival, differentiation, and are required, together with PKA, for full STARD1 expression in several contexts (simoniUnknownyearoggettoendocrinereviewsproposal pages 20-22). In primary human granulosa cells, LH elicits stronger and more sustained ERK1/2 and AKT phosphorylation than hCG at equipotent doses, consistent with a proliferative/survival bias of LH versus a steroidogenic bias of hCG.

PLC–IP3/DAG–Ca2+ signaling • LHCGR couples to Gq/11, activating PLC to produce IP3 and DAG, mobilizing Ca2+ and activating PKC. Ca2+/calmodulin-dependent kinases facilitate cholesterol transport and acute steroidogenesis, and PKC can feed into ERK signaling. In some systems hCG preferentially engages Gq/Ca2+ over LH, though Ca2+ mobilization generally requires higher agonist concentrations than cAMP (simoniUnknownyearoggettoendocrinereviewsproposal pages 20-22).

EGFR transactivation and early steroidogenic control • In Leydig and other steroidogenic models, LH/hCG rapidly transactivate EGFR and stimulate ERK/MAPK, contributing to early StAR induction and short-term steroidogenesis; in Leydig cells this can occur independently of metalloprotease-mediated shedding, indicating an intracellular transactivation route.

Angiogenic signaling and molecular targets • hCG promotes angiogenesis in the corpus luteum and placenta through multiple pathways. It directly induces endocrine gland–derived VEGF (EG‑VEGF/prokineticin‑1) and its receptors (PROKR1/2) via LHCGR → cAMP/PKA acting on CRE elements in the EG‑VEGF promoter, increasing EG‑VEGF expression and secretion in first‑trimester placental tissues. hCG also increases VEGF expression and angiogenic activity, including endothelial/pericyte responses, with evidence for VEGF upregulation via NF‑κB signaling in luteal cells. Hyperglycosylated hCG (hCG‑H) is strongly pro‑angiogenic and can act through TGFβRII independently of LHCGR, broadening angiogenic control beyond classical GPCR signaling.

Endometrial and immunomodulatory actions • At the endometrial interface, hCG increases leukemia inhibitory factor (LIF) and decreases interleukin‑6 (IL‑6) in epithelial cells, fosters stromal decidualization, and induces EGF‑family ligands (e.g., amphiregulin), which coordinate receptivity and luteal support. hCG modulates immune tolerance by attracting and expanding regulatory T cells, altering T‑cell activation markers and cytokines, and by acting on uterine NK cells via a mannose receptor (which lacks LHCGR) to regulate their proliferation. hCG also contributes to complement control (DAF, C3) in vitro and in vivo. These pleiotropic actions integrate with LHCGR‑dependent cAMP/kinase signaling to promote implantation and placentation.

Mechanistic distinction from LH (biased agonism at LHCGR) • Although hCG and LH share LHCGR, they stabilize distinct receptor conformations and produce different signaling ensembles. Relative to LH, hCG is more potent for cAMP and often produces stronger CREB/CRE‑dependent steroidogenic transcription and sustained progesterone, whereas LH tends to favor ERK/AKT activation, proliferation/survival signals, and distinct gene regulation (e.g., NRG1 inhibition, CYP19A1 control) under equipotent conditions. hCG also more readily engages β‑arrestin2 and Gq/Ca2+ and promotes receptor aggregation/endosomal signaling (casariniUnknownyearadvancearticle pages 20-21, simoniUnknownyearoggettoendocrinereviewsproposal pages 20-22).

Integrated model • hCG binding to the LHCGR ECD triggers hinge‑dependent activation of the 7TM core and coupling to Gs, Gq/11, and β‑arrestins. The dominant Gs–cAMP–PKA–CREB axis drives StAR and CYP11A1 and steroid synthesis, while β‑arrestin scaffolding, ERK/AKT, Ca2+/PKC, and EGFR transactivation calibrate acute and sustained outputs, including survival/differentiation. In reproductive tissues, hCG additionally regulates angiogenic factors (EG‑VEGF, VEGF) and endometrial/immune mediators (LIF, IL‑6, Treg/uNK/complement), thereby coordinating luteal maintenance, implantation, and placentation.

hCG Mechanism of Action summary table:

Therapeutic Applications#

Objective: To summarize therapeutic applications and documented outcomes of hCG across preclinical and clinical research, highlighting designs, doses, comparators, endpoints, efficacy and safety.

Key indications and outcomes

Male hypogonadotropic hypogonadism and induction of spermatogenesis. In a multi-center, single-arm phase III trial in adult men with hypogonadotropic hypogonadism who remained azoospermic after 16 weeks of hCG alone, adding corifollitropin alfa (150 µg every 2 weeks) to continued hCG twice-weekly (1,500 IU, uptitrated to 3,000 IU in 7/18) for 52 weeks increased mean testicular volume from 8.6 to 17.8 mL and induced spermatogenesis ≥1×10^6/mL in 14/18 (77.8%); adverse events were generally mild (estradiol increase n=3; testosterone changes n=4).

Preservation of spermatogenesis during testosterone therapy. A retrospective series of 26 hypogonadal men on testosterone replacement who received concomitant intramuscular hCG 500 IU every other day reported preserved semen parameters over up to 18 months, zero azoospermia, and 9/26 partner pregnancies; serum testosterone rose from 207 to 1,056 ng/dL; no major adverse events reported.

Cryptorchidism. A double-blind, placebo-controlled RCT in 22 boys compared FSH+hCG (FSH 150 IU twice weekly for 2 weeks, then FSH 150 IU + hCG 250 IU twice weekly for 4 weeks) versus hCG alone (hCG 250 IU twice weekly for 6 weeks). Successful descent at 12 weeks occurred in 6/18 testes with combined therapy and 6/10 with hCG alone; adding FSH conferred no benefit, and nonresponse was often associated with anatomic abnormalities; no serious adverse events occurred.

Assisted reproduction: ovulation triggering and embryo transfer adjuncts. A randomized, double-blind, double-dummy trial (n=84 cycles) showed recombinant hCG and urinary hCG were equivalent for final oocyte maturation, with similar oocyte yield, maturation, fertilization, and pregnancy outcomes; safety was comparable. In a single-center randomized, double-blind RCT (n=155 normal responders), a dual trigger (GnRH-agonist + hCG) increased oocytes retrieved (13.4 vs 11.1), MII oocytes (10.3 vs 8.6), blastocysts, clinical pregnancy (46.1% vs 24.3%), and live birth per transfer (36.2% vs 22.0%) compared with hCG alone, without notable safety issues. Completed trials in IVF/ICSI have also tested intrauterine hCG before embryo transfer; pooled contemporary analyses vary, and specific RCTs exist, but high-quality, consistent live-birth gains remain uncertain; see miscarriage section.

Recurrent miscarriage and threatened miscarriage. A Cochrane review of randomized trials (five studies; ~596 women) assessing prophylactic hCG in women with recurrent miscarriage found heterogeneous regimens and risk of bias. Pooled analyses suggested a possible reduction in miscarriage in some small trials, but overall the evidence was insufficient to recommend routine hCG prophylaxis. In threatened miscarriage with a viable fetus, a prospective double-blind RCT (n=183) using weekly IM hCG 5,000 IU until 14 weeks showed no difference in miscarriage (11% placebo vs 12% hCG; RR 1.1, 95% CI 0.63–1.6); safety was acceptable.

Obesity/weight loss claims. A criteria-based meta-analysis of randomized trials of the Simeons protocol (very-low-calorie diet plus daily low-dose hCG injections) found no added effect of hCG on weight loss, fat redistribution, hunger, or well-being versus placebo or diet alone; weight loss was attributable to the calorie restriction, not hCG.

Oncology contexts. In a retrospective cohort of ovarian tumors, serum hCG was positive in 67% of malignant versus 26.7% of benign cases, and tumor tissue expressed hCG in 68%. hCG expression correlated with LH-receptor expression and with grade/stage in some subtypes, but no overall survival difference was observed except in a subgroup (LH-R positive/FSH-R negative and hCG positive) with higher 5-year survival; findings support biomarker and potential targeting roles, not established therapy.

Neuroprotection and anti-inflammatory preclinical models. In a neonatal mouse hypoxia–ischemia model, intraperitoneal hCG administered 15–18 hours before injury reduced hippocampal and striatal tissue loss; in vitro, hCG reduced NMDA-mediated excitotoxicity and increased neurite sprouting and neuronal survival, indicating timing-dependent neuroprotection. In an inflammatory LPS-augmented neonatal HI mouse model, pre-treatment with hCG decreased cortical cystic encephalomalacia, preserved parvalbumin interneurons, and reduced microglial Iba1 immunoreactivity, supporting anti-inflammatory/neuroprotective actions (preprint; further validation warranted).

hCG-derived peptide (EA-230). Translational work on EA-230, an hCG-derived tetrapeptide, demonstrated anti-inflammatory and renoprotective effects in preclinical models, with early Phase I human studies indicating acceptable tolerability and immunomodulatory marker changes; larger efficacy trials are needed.

Summary of evidence by indication

• Established reproductive uses: hCG is effective in male hypogonadotropic hypogonadism for testicular growth and spermatogenesis, especially when combined with FSH analogs. Concomitant low-dose hCG may preserve spermatogenesis during testosterone therapy in selected men (observational). In ART, r-hCG and u-hCG are equivalent triggers, and dual trigger regimens can improve oocyte and pregnancy outcomes in normal responders.
• Mixed/negative areas: For threatened miscarriage, high-quality RCT evidence does not show benefit; for recurrent miscarriage prophylaxis, pooled evidence is inconclusive/insufficient. hCG is ineffective for weight loss beyond very-low-calorie diets. In cryptorchidism, low-dose hCG can achieve descent in a subset, but adding FSH confers no advantage and surgery remains standard when anatomic barriers exist.
• Oncology and experimental domains: hCG serves as a tumor-associated marker in several malignancies; in ovarian cancer cohorts it correlates with biology but is not an established therapeutic. Preclinical neuroprotective and anti-inflammatory effects are promising but require clinical translation. EA-230 shows early human safety and immunomodulation.

Embedded study summary table

Notes on safety. Across reproductive indications, hCG is generally well tolerated; adverse effects include estradiol-related symptoms and, rarely, thromboembolic events reported anecdotally in weight-loss misuse settings. In the HH induction trial, estradiol elevations and testosterone changes were the most frequent drug-related events; no severe safety signals emerged. For threatened miscarriage RCTs, no excess adverse events were observed with weekly 5,000 IU IM hCG to 14 weeks.

Conclusion. Clinically, hCG’s strongest therapeutic roles are in male hypogonadotropic hypogonadism (often with FSH) and as an ovulation trigger in ART, with evidence that dual-trigger strategies can enhance outcomes. Evidence does not support hCG for weight loss and does not show benefit for threatened miscarriage; prophylaxis in recurrent miscarriage remains unproven. Oncology applications are primarily as biomarkers rather than treatments. Preclinical data suggest neuroprotective and anti-inflammatory properties and hCG-derived peptide EA-230 has early human safety data, warranting further trials.

Research Evidence Quality#

Overview of the evidence base

• Extent/quality: The most comprehensive formal review is a criteria-based meta-analysis of the Simeons HCG protocol (125 IU daily plus ~500 kcal/day for 3.5–6 weeks) that examined controlled trials from 1966–1993. It found no scientific evidence that HCG improves weight loss, fat redistribution, hunger, or well-being beyond the very-low-calorie diet (VLCD) itself; most included trials were small and methodologically weak (scores 16–73/100), with only one study among the better-quality subset suggesting benefit (a clear outlier). Contemporary clinical/narrative reviews that re-examined randomized, double-blind, placebo-controlled trials reach the same conclusion: any weight loss observed with the “HCG diet” is attributable to severe caloric restriction, not HCG. Only one small RCT reported greater loss with HCG, but it had notable methodological limitations; the weight of evidence shows no added efficacy of HCG beyond the diet.

• Consensus conclusion: Across randomized trials, the 1995 meta-analysis, and later reviews, HCG does not confer clinically meaningful weight-loss benefit beyond the accompanying VLCD.

Safety, adverse events, and regulatory/professional positions

• Adverse events: Reports associated with HCG diet use include venous thromboembolism (deep vein thrombosis/pulmonary embolism), with at least one case assessed as “probable” by the Naranjo causality scale; other reported effects include headaches, mood changes (anxiety, irritability, depression), insomnia, pruritus, hypotension, hypoglycemia, constipation, delayed menses, and laboratory changes likely related to semistarvation (decreases in WBC, hematocrit, total protein, lipids; increased uric acid). Narrative safety critiques additionally flag that many OTC products contain little or no active hCG and that urinary/recombinant preparations may contain hCG variants/fragments; some variants have been linked to cancer promotion in other contexts, raising theoretical risk concerns.

• Regulatory/professional statements: Since 1975, FDA-required labeling/advertising has stated HCG is not proven effective for obesity; in 1976, the FTC ordered clinics to cease claiming HCG programs were FDA-approved or effective and required written patient notices. In 2011, FDA/FTC sent warning letters to firms marketing OTC/homeopathic HCG for weight loss, noting these were unapproved drugs with unsupported claims and that HCG is not recognized in the Homeopathic Pharmacopoeia for that use. Professional bariatric societies have issued position statements advising against the Simeons/HCG method for weight loss due to lack of efficacy and safety concerns.

Key limitations, evidence gaps, and criticisms

• Methodological limitations: Most trials are older, small, of short duration, and heterogeneous in dosing and protocols; many are of poor quality. The extreme VLCD (~500 kcal/day) used concurrently with HCG profoundly confounds attribution of any effect to HCG itself.

• Product/biologic variability: Commercial preparations vary widely; many non-injectable OTC products appear to contain little or no active hCG or have uncertain absorption, undermining both efficacy claims and safety generalizability. Urinary/recombinant preparations often include variant fragments with unclear clinical effects and theoretical oncologic risks.

• Safety evidence gaps: There is a paucity of prospectively collected safety data and long-term outcomes for HCG used for weight loss; safety signals largely come from case reports and physiological changes during semistarvation, limiting causal inference.

• Criticisms: Claims of fat redistribution, appetite suppression, or enhanced well-being lack empirical support in blinded RCTs and the meta-analysis. Marketing of homeopathic/OTC formulations without active hCG or demonstrated bioavailability is criticized as misleading and potentially unethical, and regulatory bodies have repeatedly acted against unsupported claims.

• The evidence base for HCG as a weight-loss aid is extensive enough to conclude that it is ineffective beyond the effects of a severe VLCD, with consistent results across RCTs and a criteria-based meta-analysis. Safety concerns exist, including thromboembolic events and theoretical risks related to product impurities/variants, but high-quality long-term safety data are lacking. Regulatory and professional bodies uniformly advise against its use for weight loss.

Evidence Gaps and Limitations#

The current evidence base for HCG consists primarily of preclinical studies. Key limitations include:

• No completed randomized controlled trials in humans
• Most data derived from animal models, limiting direct translatability
• Publication bias may favor positive results
• Long-term safety data in humans is not available
• Optimal dosing for human applications has not been established

Key Research Findings#

Human chorionic gonadotrophin (hCG) for preventing miscarriage, published in Cochrane Database of Systematic Reviews (Morley LC et al., 2013; PMID: 23440828):

• The study showed review of 5 trials
• The study showed review of 5 trials ; pooled data suggested possible reduction in miscarriage but effect lost after excluding lower quality trials; evidence insufficient to recommend routine hCG prophylaxis

Related Reading#

• HCG research studies and evidence
• HCG dosing protocols
• HCG side effects profile
• Gonadorelin research guide
• HMG research guide